Literature DB >> 353219

Resistance of neoplasms to immunological destruction: role of a macrophage chemotaxis inhibitor.

G R Pasternack, R Snyderman, M C Pike, R J Johnson, H S Shin.   

Abstract

Several tissue culture lines of 6C3HED, a murine lymphoma, were more susceptible to immunologic destruction in vivo than the highly virulent 6C3HED line maintained by serial intramuscular transplantation. The attenuated tissue culture cells were rejected by normal syngeneic recipients, but thymectomized mice were unable to reject attenuated cells. In such mice, the growth rate of attenuated cells was equivalent to the growth rate of virulent cells in normal syngeneic mice. The increased susceptibility of attenuated cells to destruction by syngeneic hosts was shown to correlate with decreased production by the tumor cells of a macrophage chemotaxis inhibitor, and not with altered antigen density. In addition, when inhibitor isolated from virulent cells was administered to mice challenged with attenuated cells, the latter cells became virulent in vivo. When attenuated and virulent cells were administered simultaneously in the same host, the attenuated cells were able to develop into progressively growing tumors. The data suggest that the successful growth of neoplastic cells in normal may require tumor cells to produce factors which subvert the ability of the host to mobilize macrophages rapidly at the tumor site.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 353219      PMCID: PMC2184921          DOI: 10.1084/jem.148.1.93

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  18 in total

1.  Further studies in vitro of transplantable mouse lymphosarcoma MB (T 86157).

Authors:  W M DE BRUYN; G O GEY
Journal:  Acta Unio Int Contra Cancrum       Date:  1952

2.  Inhibition of macrophage chemotaxis by neoplastic and other rapidly proliferating cells in vitro.

Authors:  S J Normann; E Sorkin
Journal:  Cancer Res       Date:  1977-03       Impact factor: 12.701

3.  An inhibitor of macrophage chemotaxis produced by neoplasms.

Authors:  R Snyderman; M C Pike
Journal:  Science       Date:  1976-04-23       Impact factor: 47.728

4.  The immune recognition of TA3 tumors, its facilitation by endotoxin, and abrogation by ascites fluid.

Authors:  J Grohsman; A Nowotny
Journal:  J Immunol       Date:  1972-11       Impact factor: 5.422

Review 5.  Immunosuppression and the role of suppressive factors in cancer.

Authors:  I Kamo; H Friedman
Journal:  Adv Cancer Res       Date:  1977       Impact factor: 6.242

Review 6.  The role of macrophages in defense against neoplastic disease.

Authors:  M H Levy; E F Wheelock
Journal:  Adv Cancer Res       Date:  1974       Impact factor: 6.242

7.  Macrophage migratory dysfunction in cancer. A mechanism for subversion of surveillance.

Authors:  R Snyderman; M C Pike
Journal:  Am J Pathol       Date:  1977-09       Impact factor: 4.307

8.  Antibody-mediated suppression of tumor growth. III. Molecular assay of murine IgG1 alloantibody required to cause tumor suppression in vivo.

Authors:  R J Johnson; G R Pasternack; B E Drysdale; H S Shin
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

9.  Depression of macrophage function by a factor produced by neoplasms: a merchanism for abrogation of immune surveillance.

Authors:  M C Pike; R Snyderman
Journal:  J Immunol       Date:  1976-10       Impact factor: 5.422

10.  Antiinflammatory effects of murine malignant cells.

Authors:  R M Fauve; B Hevin; H Jacob; J A Gaillard; F Jacob
Journal:  Proc Natl Acad Sci U S A       Date:  1974-10       Impact factor: 11.205

View more
  11 in total

Review 1.  Macrophage infiltration and tumor progression.

Authors:  S J Normann
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

Review 2.  Disordered function of mononuclear phagocytes in malignant disease.

Authors:  R J Sokol; G Hudson
Journal:  J Clin Pathol       Date:  1983-03       Impact factor: 3.411

3.  Stereospecific chemoattraction of lymphoblastic cells by gradients of lysophosphatidylcholine.

Authors:  R D Hoffman; M Kligerman; T M Sundt; N D Anderson; H S Shin
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

4.  Chemotaxis of purified human monocytes in vitro: lack of accessory cell requirement.

Authors:  W Falk; E J Leonard
Journal:  Infect Immun       Date:  1982-05       Impact factor: 3.441

5.  Alveolar macrophage dysfunction in malignant lung tumours.

Authors:  E Lemarie; P Carre; M F Legrand; M Lavandier; E Boissinot; M Renoux; G Renoux
Journal:  Thorax       Date:  1984-06       Impact factor: 9.139

Review 6.  Effects of tumor growth on host defenses.

Authors:  G J Cianciolo; R Snyderman
Journal:  Cancer Metastasis Rev       Date:  1986       Impact factor: 9.264

7.  Leukocyte chemoattraction by 1,2-diacylglycerol.

Authors:  T M Wright; R D Hoffman; J Nishijima; L Jakoi; R Snyderman; H S Shin
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

8.  Defective monocyte chemotactic responsiveness in patients with multiple myeloma and benign monoclonal gammapathy.

Authors:  F Dammacco; A Miglietta; M T Ventura; L Bonomo
Journal:  Clin Exp Immunol       Date:  1982-02       Impact factor: 4.330

9.  Hydrogen peroxide-releasing function of chemically elicited and immunologically activated macrophages: differential response to wheat germ lectin and concanavalin A.

Authors:  H Tomioka; H Saito
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

10.  Antitumour potential of pleural cavity macrophages in lung cancer patients without malignant effusion.

Authors:  S Kimura; S Sone; K Takahashi; T Uyama; T Ogura; Y Monden
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.